Astellas launches $3.5 billion hostile bid for OSI
This article was originally published in Scrip
Executive Summary
Astellas has launched a tender offer to acquire OSI Pharmaceuticals, despite the cancer, obesity and diabetes-focused company having previously turned down discussion requests.